SAN DIEGO, Nov. 30 /PRNewswire-FirstCall/ -- CryoCor, Inc. , a medical device company focused on the treatment of cardiac arrhythmias, announced today that Gregory M. Ayers, Founder and Chief Executive Officer, is scheduled to present at the First Albany Capital Annual Growth Conference, December 7, 2005 at 12:40 pm ET at The Mandarin Oriental Hotel in New York.
A live Web cast and recording of the presentation will be available online from the investor relations page of the Company’s corporate Web site at http://ir.cryocor.com. The recording will remain available on CryoCor’s Web site until March 7, 2006.
About CryoCor
CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The company’s product, the CryoCor Cardiac Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The CryoCor System has been approved in Europe for the treatment of atrial fibrillation and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the CryoCor Cardiac Cryoablation System for the treatment of atrial fibrillation, and has submitted a PMA for the treatment of Atrial Flutter. For more information please visit the Company’s website at CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company’s product, the CryoCor Cardiac Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The CryoCor Cardiac Cryoablation System has been approved in Europe for the treatment of atrial fibrillation and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the CryoCor Cardiac Cryoablation System for the treatment of atrial fibrillation, and has submitted a PMA for the treatment of atrial flutter. For more information please visit the Company’s website at http://www.cryocor.com
Contacts: CryoCor The Ruth Group Gregory J. Tibbitts Stephanie Carrington / Nick Laudico (investors) Chief Financial Officer (646) 536-7017 / 7030 (858) 909-2200 scarrington@theruthgroup.comgtibbitts@cryocor.comnlaudico@theruthgroup.com Jason Rando (media) (646) 536-7025 jrando@theruthgroup.com
Audio: http://ir.cryocor.comCryoCor, Inc.
CONTACT: Gregory J. Tibbitts, Chief Financial Officer of CryoCor,+1-858-909-2200, gtibbitts@cryocor.com; or Investors - StephanieCarrington, +1-646-536-7017, scarrington@theruthgroup.com, or Nick,Laudico, +1-646-536-7030, nlaudico@theruthgroup.com; or Media - JasonRando, +1-646-536-7025, jrando@theruthgroup.com, all of The Ruth Group forCryoCor
Web site: http://www.cryocor.com/
Company News On-Call: http://www.prnewswire.com/comp/159222.html /
